Analysts Set OptiNose Inc (NASDAQ:OPTN) Target Price at $27.25

OptiNose Inc (NASDAQ:OPTN) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $27.25.

OPTN has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. Piper Jaffray Companies set a $29.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Finally, Zacks Investment Research upgraded shares of General Moly from a “sell” rating to a “hold” rating in a research report on Thursday.

NASDAQ OPTN traded down $0.71 during mid-day trading on Wednesday, reaching $7.29. 11,825 shares of the stock were exchanged, compared to its average volume of 206,487. OptiNose has a 1-year low of $5.66 and a 1-year high of $28.04. The firm’s fifty day simple moving average is $7.22. The firm has a market capitalization of $318.12 million, a PE ratio of -2.88 and a beta of 0.93. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.95 and a quick ratio of 6.74.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Thursday, May 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.01. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. The firm had revenue of $4.48 million for the quarter, compared to analyst estimates of $4.35 million. On average, analysts forecast that OptiNose will post -2.97 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA lifted its holdings in shares of OptiNose by 1,569.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after acquiring an additional 3,766 shares in the last quarter. Stifel Financial Corp acquired a new position in shares of OptiNose during the 4th quarter valued at $63,000. Two Sigma Advisers LP acquired a new position in shares of OptiNose during the 4th quarter valued at $135,000. Rhumbline Advisers lifted its holdings in shares of OptiNose by 58.5% during the 4th quarter. Rhumbline Advisers now owns 23,709 shares of the company’s stock valued at $147,000 after acquiring an additional 8,748 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of OptiNose by 31.9% during the 4th quarter. Bank of America Corp DE now owns 53,593 shares of the company’s stock valued at $332,000 after acquiring an additional 12,961 shares in the last quarter. Institutional investors own 63.68% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Featured Story: How do CD ladders protect against rising interest rates?

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.